Navigation Links
$37 million financing for company based on macular degeneration research
Date:10/9/2007

New Haven, Conn. Optherion, Inc. a company that will use groundbreaking discoveries by scientists at Yale and the University of Iowa to develop products to diagnose and treat Age-related Macular Degeneration (AMD) and other related chronic diseases has received $37 million in start-up financing.

Discoveries in 2005 by Josephine Hoh at Yale School of Public Health and Gregory Hageman at the University of Iowa linked Complement Factor H (CFH) and Complement Factor B (CFB) two elements of the alternate complement pathway of the immune system with AMD. These factors are involved in inflammatory responses, which can cause tissue damage when improperly controlled.

AMD is caused by degeneration of the macula, the region of the retina responsible for central vision. There are two forms of AMD, dry and wet. AMD is the leading cause of blindness in people over age 60 in the developed world. Dry AMD is the most common form, while wet AMD is a less prevalent and more aggressive form of the disease with growth of new blood vessels into the retina.

Optherions initial focus will be to develop disease-modifying therapies to prevent loss of vision in patients with dry AMD, as well as a portfolio of tests that predict, diagnose and monitor progression of the disease.

AMD is unusual because it is a widespread disease that is caused by common variations in only a few specific genes. Approximately 50% of patients with AMD suffer from variations in the CFH gene, and 74% of the disease can be explained by variations in the CFH and CFB genes combined. Variants in other genes, found on Chromosome 10, are also implicated in AMD, and will be a further focus for the companys development of therapeutic and diagnostic products.

In the future, the companys proprietary technologies will also be extended to the possible diagnosis and treatment of other chronic diseases related to the alternative complement system.

We are extraordinarily pleased to have these discoveries so rapidly and substantially supported as they are translated into valuable diagnostics, said John Puziss, Director of Technology Licensing for Yales Office of Cooperative Research. We also want to thank the Sackler Fund for the Arts and Sciences and Raymond and Beverly Sackler, long standing supporters of medical research and the Yale School of Medicine, for the grant that funded this landmark research and the Verto Institute founded and directed by Jonathan and Richard Sackler that continues to fund Dr. Hohs projects in ophthalmology and other diseases.

Colin J. Foster, Optherions President and CEO, said, We are embarking on a program that exploits a new and exciting area of research with breakthrough potential in areas of high unmet medical need. Foster is the former CEO of Bayer Pharmaceuticals in the U.S. and Region Head for Bayer Pharmaceuticals in North America.

Among the sources of capital for the financing are: Quaker BioVentures, Philadelphia; Domain Associates, Princeton, NJ and San Diego; Johnson & Johnson Development Corporation, New Brunswick, NJ; Purdue Pharmaceutical Products L.P., Stamford, CT; Pappas Ventures, Research Triangle Park, NC; Biogen Idec New Ventures, Cambridge, MA and GE Healthcare Financial Services, Chicago, IL.

The successful completion of this Series A financing will enable the company to advance the work of Dr. Hageman, Dr. Hoh and others, and hopefully transform the diagnosis and treatment of dry age-related macular degeneration, said David Scheer, Chairman of the Optherion Board of Directors.


'/>"/>

Contact: Janet Rettig Emanuel
janet.emanuel@yale.edu
203-432-2157
Yale University
Source:Eurekalert

Related medicine news :

1. Drug May Make Breathing Easier for Millions
2. Hundred million dollar gift for malaria institute
3. George Bush pledges 200 million dollars for AIDS relief
4. Hope for 11 million children facing death from illnesses
5. The forgotten epidemic killing millions
6. WHO and UNAIDS unveil plan to get 3 million AIDS patients on treatment by 2005
7. Over Six Million HIV Infected People In South Africa- Finds A Survey
8. Tanzanian Government Sanctions $20 Million For AIDS Arug
9. Grant of $7 million for Orissa Medical College from Japan
10. Merck to pay $ 253.5 million to Vioxx victim family
11. GlaxoSmithKline to Supply United States with 8 Million flu vaccine, Fluarix
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/26/2016)... NY (PRWEB) , ... May 26, 2016 , ... ... founder of Mehling Orthopedics and chief medical officer of Blue Horizon International (BHI), ... and Regeneration. The conference was held during May 5-6, 2016 in Chicago, IL, ...
(Date:5/26/2016)... ... May 26, 2016 , ... ... oncology professionals, has added National Cancer Institute-designated University of Virginia (UVA) Cancer ... this new partnership, OncLive’s editorial and marketing teams will publicize and promote public ...
(Date:5/26/2016)... ... May 26, 2016 , ... Metcalf & Associates’ ... 20 years of experience in leading technology and human resources operations for health ... teaching, Morrow-Fox will be featured on Metcalf’s VoiceAmerica radio show , Innovative ...
(Date:5/26/2016)... ... May 26, 2016 , ... ... is seeking nominations to serve on its Accreditation and Standards Committees and ... “RadSite’s quality-benchmarking activities incorporate key process and outcome measures, with the ultimate ...
(Date:5/26/2016)... , ... May 26, 2016 , ... According to the ... an industry filled with chemical-laden beauty products, one company is going against the norm ... you: Mad Hippie. The rising star in the green space is proud to announce ...
Breaking Medicine News(10 mins):
(Date:5/26/2016)... 2016 Since its commercial introduction ... essential life science tool for conducting genetic studies in ... reveals in its new report that the industry sits ... powered by a range of new applications in the ... http://photos.prnewswire.com/prnh/20140723/694805 ) , Since the ...
(Date:5/25/2016)... GERMANTOWN, Maryland , May 25, 2016 /PRNewswire/ ... Frankfurt Prime Standard: QIA) today announced that the company has ... GmbH to develop and commercialize predictive assays in oncology. An ... a marker to predict effectiveness of anthracycline treatment in triple ... are pleased to partner with Therawis, which developed the PITX2 ...
(Date:5/25/2016)... As illustrated by the Spring ... the numbers and momentum of cannabis in the US ... billions, more research and development push the sector forward. ... Legal Marijuana Markets Report  from from ArcView Market Research ... the increase in sector is attributed to adult use ...
Breaking Medicine Technology: